Entropy Technologies LP Makes New $378,000 Investment in Amedisys, Inc. $AMED

Key Points

• Entropy Technologies LP has purchased 4,081 shares of Amedisys, Inc., valued at approximately $378,000, marking a noteworthy investment in the health services sector.
• Analysts have mixed views on Amedisys, with Royal Bank of Canada maintaining an "outperform" rating and a price target of $100.00, while Wall Street Zen downgraded the stock to a "buy" rating.
• Amedisys reported a 5.2% increase in quarterly revenue year-over-year, achieving $621.86 million, and outperforming analyst expectations for earnings per share.

Entropy Technologies LP acquired a new position in Amedisys, Inc. (NASDAQ:AMED - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,081 shares of the health services provider's stock, valued at approximately $378,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Cerity Partners LLC bought a new position in Amedisys in the 1st quarter worth approximately $463,000. Fifth Third Bancorp increased its stake in shares of Amedisys by 68.1% in the 1st quarter. Fifth Third Bancorp now owns 348 shares of the health services provider's stock valued at $32,000 after buying an additional 141 shares during the period. Teacher Retirement System of Texas acquired a new stake in shares of Amedisys in the 1st quarter valued at $817,000. M&T Bank Corp acquired a new stake in shares of Amedisys in the 1st quarter valued at $315,000. Finally, CWM LLC increased its stake in shares of Amedisys by 16.1% in the 1st quarter. CWM LLC now owns 2,470 shares of the health services provider's stock valued at $229,000 after buying an additional 343 shares during the period. Institutional investors and hedge funds own 94.36% of the company's stock.

Amedisys Trading Up 0.0%

NASDAQ AMED traded up $0.03 on Monday, reaching $101.01. The company had a trading volume of 1,060,057 shares, compared to its average volume of 780,222. The stock's 50 day moving average is $98.02 and its 200-day moving average is $94.76. The stock has a market cap of $3.32 billion, a price-to-earnings ratio of 39.30, a PEG ratio of 1.34 and a beta of 0.89. The company has a quick ratio of 1.36, a current ratio of 1.36 and a debt-to-equity ratio of 0.26. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $101.02.

Amedisys (NASDAQ:AMED - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The health services provider reported $1.54 EPS for the quarter, beating analysts' consensus estimates of $1.39 by $0.15. The business had revenue of $621.86 million during the quarter, compared to the consensus estimate of $614.61 million. Amedisys had a return on equity of 12.91% and a net margin of 3.56%. The firm's revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.98 earnings per share. Equities analysts predict that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut Amedisys from a "strong-buy" rating to a "buy" rating in a research note on Saturday, May 24th.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.